psychedelic medicine

In recent years, the landscape of medicine and mental health has been rapidly evolving, with psychedelic therapies taking center stage. As an advocate and investor in the psychedelic space, I’m excited to share insights into what I believe is the dawn of a trillion-dollar industry. The...

This article was originally published on Microdose and appears here with permission. The psychedelic medicine community has lost one of its great figures as Dr. Roland Griffiths has passed away. Roland Griffiths, Ph.D., was a Professor of Psychiatry and Neurosciences at the Johns Hopkins University...

In our latest TDR Psychedelics Exclusive, we welcome Melissa Lavasani to the mic. Lavasani is Founder and Chief Executive Officer at Psychedelic Medicine Coalition and the Founder and President of the Psychedelic Medicine PAC. The Psychedelic Medicine PAC focuses on securing federal...

The quest to advance psychedelic medicine in Canada received a big boost today. The Minister of Mental Health and Addictions, Carolyn Bennett, announced an investment of nearly $3 million through the Canadian Institutes of Health Research. This funding will support three clinical...

On this episode of Trade to Black, we’re talking about the psychedelics industry coming of age with Zappy Zapolin, on the eve of Wonderland in Miami early next month. Wonderland is the biggest dedicated psychedelics conference that brings together some of the leading...

Article by Jason Najum.  Psychedelic startups face a more challenging time raising capital amid market volatility, the prospect of rate hikes, and recession fears, but that could ultimately help the industry to mature. "This period of market volatility and less appetite for risk is...

Novamind Inc. (CSE: NM) (OTCQB: NVMDF) (FSE: HN2) announced Monday a CA$5 million ($3.95 million) private placement with an institutional investor. The mental health company, specialized in psychedelic medicine, confirmed it has signed a securities purchase agreement with a single...

Mydecine Innovations Group (NEO:MYCO) (OTC: MYCOF) (FSE:0NFA) reported its financial results on Tuesday and provided a business update for the third quarter ended September 30. Q3 2021 Financial Highlights Net loss attributable to common stockholders was $4.5 million, or a basic and diluted loss...

Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) confirmed Friday it will commence trading on the Nasdaq Capital Market under the ticker symbol “MNMD” on April 27th. The psychedelic medicine biotech company reported its subordinate voting shares have obtained the necessary...

Psychedelic medicine biotech company MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ) reported Monday the results of a study on MDMA dosing optimization utilizing personalized medicine. The study was conducted at the University Hospital Basel Liechti Lab, in Basel, Switzerland. The company said it...